糖尿病血脂异常的坚持与改变2019  

Insistence and progress in diabetic patients with dyslipidemia in 2019

作　　者：李祎 崔炜[1] LI Yi;CUI Wei(First Department of Cardiology,the Second Hospital of Hebei Medical University,Institute of Cardiocerebrovascular Disease of Hebei Province,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二医院河北省心脑血管病研究所心内一科,河北石家庄050000

出　　处：《河北医科大学学报》2020年第3期249-253,共5页Journal of Hebei Medical University

摘　　要：目前糖尿病合并血脂异常发生率很高,控制糖尿病患者的血脂异常有助于改善其远期预后。2019年关于糖尿病合并血脂异常仍然坚持以低密度脂蛋白胆固醇为降脂治疗的首要目标,最新指南中增加了载脂蛋白B作为新的降脂治疗的目标,对于极高危糖尿病患者设定了更低的低密度脂蛋白胆固醇目标值;仍然坚持以他汀类药物为糖尿病患者降脂治疗的核心药物,在他汀类药物治疗欠佳的情况下,可联合应用依折麦布,最新指南也推荐前蛋白转化酶枯草溶菌素9/kexin9型抑制剂作为联合用药。The incidence of patients with diabetic dyslipidemia is very high,so it is beneficial for their long-term prognosis to control dyslipidemia in patients with diabetes mellitus.With regard to diabetes combined with dyslipidemia,low-density lipoprotein cholesterol is still the primary target of lipid-lowering therapy.But apolipoprotein B is another new important target for lipid-lowering treatments in the latest guidelines,and a lower low-density lipoprotein cholesterol concentration is set for diabetic patients with the very high-risk cardiovascular risk.Statin is still the cornerstone in lipid-lowering therapy.Not only ezetimibe but,lately,proprotein convertase subtilisin/kexin type 9 inhibitors could be used as combination drugs,if the targets cannot achieve with statins alone.

关 键 词：糖尿病 血脂异常 脂蛋白类 LDL 

分 类 号：R587.1[医药卫生—内分泌]